Xin Zheng

US Patent:

6403077, Jun 11, 2002

Filed:

Nov 6, 1997

Appl. No.:

08/968905

Inventors:

Terry B. Strom - Brookline MA
Xin Xiao Zheng - Brookline MA
Alan Steele - Wellesley MA

Assignee:

Beth Israel Hospital Association - Boston MA

International Classification:

A61K 3820

US Classification:

424 852, 514 2, 514 8, 514 12

Abstract:

Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e. g. , multiple myeloma) in a patient.

US Patent:

6410008, Jun 25, 2002

Filed:

Dec 12, 1994

Appl. No.:

08/355502

Inventors:

Terry B. Strom - Brookline MA
Xin Xiao Zheng - Brookline MA
Alan Steele - Wellesley MA

Assignee:

Beth Israel Hospital Association - Boston MA

International Classification:

C07K 1454

US Classification:

424 852, 530351, 530402, 514 2, 514 8, 514 12, 435 697, 435 712, 4353201, 4352523

Abstract:

Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.

US Patent:

6770272, Aug 3, 2004

Filed:

May 14, 2002

Appl. No.:

10/145481

Inventors:

Terry B. Strom - Brookline MA
Xin Xiao Zheng - Brookline MA
Alan Steele - Wellesley MA

Assignee:

Beth Israel Hospital Association - Boston MA

International Classification:

A61K 3820

US Classification:

424 852, 514 2, 514 8, 514 12, 514866, 530402

Abstract:

Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.

US Patent:

6797263, Sep 28, 2004

Filed:

May 14, 2001

Appl. No.:

09/855313

Inventors:

Terry B. Strom - Brookline MA
Wlodzimierz Maslinski - Warsaw, PL
Xin Xiao Zheng - Brookline MA
Yon Su Kim - Seoul, KR
Sylvie Ferrari-Lacraz - Geneva, CH

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 3819

US Classification:

424 851, 424 852, 435 695, 435 6952, 435 697, 435 711, 435320, 530351

Abstract:

Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.

US Patent:

7018626, Mar 28, 2006

Filed:

May 14, 2002

Appl. No.:

10/145517

Inventors:

Terry B. Strom - Brookline MA, US
Xin Xiao Zheng - Brookline MA, US
Alan Steele - Wellesley MA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

C07K 14/52
A61K 38/20

US Classification:

424 852, 530351, 530402, 514 2, 514 8, 514 12

Abstract:

Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e. g. , multiple myeloma) in a patient.

US Patent:

7347995, Mar 25, 2008

Filed:

May 25, 2004

Appl. No.:

10/853466

Inventors:

Terry B. Strom - Brookline MA, US
Wlodzimierz Maslinski - Warsaw, PL
Xin Xiao Zheng - Brookline MA, US
Yon Su Kim - Seoul, KR
Sylvie Ferrari-Lacraz - Geneva, CH

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

C07K 14/54
C07K 14/435
A61K 38/00
A61K 38/20

US Classification:

424 851, 424 852, 435 695, 435 6952, 435 697, 435 711, 530351

Abstract:

Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.

US Patent:

7579439, Aug 25, 2009

Filed:

Dec 30, 2003

Appl. No.:

10/749699

Inventors:

Terry B. Strom - Brookline MA, US
Xian Chang Li - Newton MA, US
Xin Xiao Zheng - Pittsburgh PA, US

Assignee:

Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

C07K 14/55
A61K 45/00
A61K 39/385
C07K 14/47

US Classification:

530351, 424 852, 4241921, 514 12

Abstract:

The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e. g. , pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death.

US Patent:

7741271, Jun 22, 2010

Filed:

Mar 14, 2005

Appl. No.:

11/080091

Inventors:

Vijay K. Kuchroo - Newton MA, US
Sumone Chakravarti - Oakland CA, US
Terry Strom - Brookline MA, US
Xin Xiao Zheng - Wellesley MA, US
Jennifer Meyers - Brighton MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA
Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 38/00
A61K 45/00
A61K 47/00

US Classification:

514 2, 4242781

Abstract:

The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.